Bellevue Group AG Has $1.82 Million Stock Holdings in BeiGene, Ltd. (NASDAQ:BGNE)
Bellevue Group AG lessened its holdings in BeiGene, Ltd. (NASDAQ:BGNE – Free Report) by 82.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,200 shares of the company’s stock after selling 48,035 shares during the quarter. Bellevue Group AG’s holdings in BeiGene were worth $1,819,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of BeiGene in the 1st quarter valued at $25,000. Toronto Dominion Bank acquired a new stake in shares of BeiGene in the 1st quarter valued at $27,000. Headlands Technologies LLC acquired a new stake in shares of BeiGene in the 2nd quarter valued at $40,000. PNC Financial Services Group Inc. boosted its holdings in shares of BeiGene by 26.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 244 shares of the company’s stock valued at $54,000 after purchasing an additional 51 shares in the last quarter. Finally, Exchange Traded Concepts LLC acquired a new stake in shares of BeiGene in the 2nd quarter valued at $90,000. Institutional investors and hedge funds own 48.55% of the company’s stock.
BeiGene Stock Down 1.3 %
Shares of BGNE traded down $2.46 during trading hours on Wednesday, hitting $181.69. The stock had a trading volume of 15,600 shares, compared to its average volume of 221,357. The company has a debt-to-equity ratio of 0.05, a current ratio of 3.16 and a quick ratio of 2.91. The firm has a 50 day simple moving average of $181.60 and a 200-day simple moving average of $194.92. The firm has a market capitalization of $17.31 billion, a P/E ratio of -19.89 and a beta of 0.59. BeiGene, Ltd. has a 1-year low of $156.56 and a 1-year high of $280.62.
BeiGene (NASDAQ:BGNE – Get Free Report) last issued its earnings results on Thursday, November 9th. The company reported $2.01 EPS for the quarter, beating the consensus estimate of ($3.38) by $5.39. The company had revenue of $781.30 million during the quarter, compared to the consensus estimate of $596.75 million. BeiGene had a negative return on equity of 23.83% and a negative net margin of 43.53%. The firm’s revenue for the quarter was up 101.6% compared to the same quarter last year. During the same period last year, the business posted ($5.39) EPS. Sell-side analysts predict that BeiGene, Ltd. will post -6.99 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on the company. Bank of America dropped their price target on BeiGene from $224.13 to $212.00 and set a “neutral” rating for the company in a research note on Wednesday, September 20th. StockNews.com upgraded BeiGene from a “sell” rating to a “hold” rating in a research note on Thursday, November 9th. Royal Bank of Canada assumed coverage on BeiGene in a research note on Tuesday, September 12th. They issued an “outperform” rating and a $259.00 price target for the company. Morgan Stanley lowered their target price on BeiGene from $321.00 to $319.00 and set an “overweight” rating for the company in a research report on Tuesday, August 29th. Finally, Macquarie assumed coverage on BeiGene in a research report on Monday, September 11th. They set an “outperform” rating and a $259.00 target price for the company. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, BeiGene has a consensus rating of “Moderate Buy” and an average price target of $278.08.
Read Our Latest Analysis on BGNE
About BeiGene (Free Report)
BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider BeiGene, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and BeiGene wasn’t on the list.
While BeiGene currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Which stocks are major institutional investors including hedge funds and endowments buying in today’s market? Click the link below and we’ll send you MarketBeat’s list of thirteen stocks that institutional investors are buying up as quickly as they can.